Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of
 elotuzumab in clinical practice in Japan.
Inclusion Criteria:

 -  All patients with relapsed or refractory multiple myeloma who are beginning to receive
 elotuzumab at the selected sites will be included in this surveillance study

 Exclusion Criteria:

 -  Not Applicable